A closely watched experimental heart drug from Novartis and Ionis Pharmaceuticals has failed to achieve its main goal in a major late-stage clinical trial, raising fresh questions about one of the most promising targets in cardiovascular medicine.
Novartis announced that pelacarsen, an experimental drug designed to lower lipoprotein(a), or Lp(a), failed to significantly reduce major cardiovascular events in patients with established cardiovascular disease and elevated levels of the genetically inherited risk factor.
The disappointing result came from the Phase III Lp(a)HORIZON trial, one of the most closely watched cardiovascular drug studies in recent years.
While pelacarsen successfully lowered Lp(a) levels, the drug did not meet its primary endpoint of reducing a combination of cardiovascular death, non-fatal heart attacks, non-fatal strokes and urgent coronary revascularization requiring hospitalization compared with placebo.
The result marks a significant setback for Swiss pharmaceutical giant Novartis and its partner Ionis Pharmaceuticals — and could have broader implications for the emerging race to develop medicines targeting Lp(a).
A Major Test for a New Approach to Heart Disease
Lp(a), often referred to as a genetically determined cardiovascular risk factor, has become one of the hottest areas of heart disease research.
Unlike traditional cholesterol measures, elevated Lp(a) levels are largely inherited and can significantly increase the risk of cardiovascular disease. For years, researchers have believed that dramatically lowering Lp(a) could potentially reduce heart attacks, strokes and other serious cardiovascular events.
Pelacarsen appeared capable of doing the first part.
The drug successfully reduced Lp(a) levels.
But the much bigger question — whether lowering the biomarker would actually translate into fewer heart attacks and strokes — was not answered in the way investors and researchers had hoped.
According to Novartis, the Phase III Lp(a)HORIZON trial failed to demonstrate a statistically significant reduction in the study’s primary composite cardiovascular endpoint compared with placebo.
More Than 8,000 Patients Were Studied
The setback is particularly significant because of the scale and importance of the trial.
The long-term study involved more than 8,000 patients with established cardiovascular disease and elevated Lp(a), making it one of the largest and most important tests yet of the theory that aggressively lowering the particle can improve real-world cardiovascular outcomes.
The findings have now raised a difficult scientific question:
Is lowering Lp(a) alone enough to prevent heart attacks and strokes?
For Novartis, the answer from pelacarsen’s pivotal trial was disappointing.
However, experts and analysts caution that the results may not completely close the door on Lp(a)-targeting therapies. Different drugs may lower the particle to different degrees, and ongoing studies could help determine whether deeper or earlier intervention produces better cardiovascular outcomes.
Other pharmaceutical companies, including Amgen and Eli Lilly, are also developing experimental treatments targeting Lp(a), meaning the pelacarsen results are likely to be closely scrutinized across the entire cardiovascular drug industry.
Blow to Novartis’ Drug Pipeline
The failed trial comes at an important time for Novartis.
The company has been counting on several late-stage experimental medicines to help drive future growth as it faces patent expirations and potential revenue pressure from the loss of exclusivity surrounding some of its major products, including blockbuster heart medicine Entresto.
Pelacarsen had been viewed as one of the company’s important future growth opportunities.
Reuters reported that analysts had included pelacarsen among several key Novartis pipeline programs expected to generate substantial future sales if successful.
The negative result triggered an immediate reaction from investors, with both Novartis and Ionis shares coming under pressure following the announcement, according to multiple financial news reports.
Pelacarsen Lowered the Risk Factor — But Not the Risk
Perhaps the most striking aspect of the trial is the disconnect between the drug’s biological effect and its clinical results.
Pelacarsen did what it was designed to do: it lowered Lp(a).
But patients did not experience a statistically significant reduction in the major cardiovascular events measured by the trial.
That gap could prove critical for future research.
Drug developers increasingly face the challenge of proving that changing a biological marker leads to meaningful improvements for patients. A drug can successfully alter cholesterol, proteins or other risk factors — but regulators, doctors and patients ultimately need evidence that treatment reduces illness, hospitalization or death.
The pelacarsen result is now likely to become an important case study in cardiovascular drug development.
Novartis Says the Research Still Matters
Despite missing the primary endpoint, Novartis said the trial remains important for understanding the relationship between Lp(a) and cardiovascular disease.
The company is expected to provide more detailed data from the Lp(a)HORIZON trial, which could offer clues about whether certain patient groups benefited more than others or whether the degree and duration of Lp(a) reduction played a role.
Those details will be closely watched by cardiologists, researchers and competing drugmakers.
For now, however, pelacarsen’s results have dealt a major blow to expectations surrounding the drug.
What Happens Next?
The failure of pelacarsen to meet its main goal does not necessarily mean the end of research into Lp(a).
Instead, the results could intensify efforts to understand several key questions:
- How much must Lp(a) be reduced to produce cardiovascular benefits?
- Should treatment begin earlier in patients’ lives?
- Are some high-risk patient groups more likely to benefit?
- Could deeper Lp(a) reduction produce different results?
- Will competing drugs using different technologies perform better?
The answers could reshape the future of cardiovascular medicine.
For Novartis and Ionis, however, the immediate reality is clear: one of the most closely watched experimental heart drugs in development has suffered a major setback.
Pelacarsen successfully lowered a dangerous cardiovascular risk factor. But in the trial that mattered most, lowering that number was not enough to deliver the outcome patients and investors were waiting for.
And now, the biggest question facing the entire Lp(a) drug race is whether another company can prove what pelacarsen could not.
WWC ONE MEDIA J.M.S
Leave a Reply